Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 112, Issue 1, 2004, Pages 74-79

  Christodoulakos, George E ^a   Panoulis, Constantinos P C ^a   Lambrinoudaki, Irene V ^a   Dendrinos, Spyros G ^a   Rizos, Demetrios A ^a   Creatsas, George C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Homocysteine; HRT; Tibolone

Indexed keywords

ESTROGEN DERIVATIVE; HOMOCYSTEINE; MEDROXYPROGESTERONE ACETATE; TIBOLONE;

ADULT; AGE; ARTICLE; CHRONOLOGY; CONTROLLED STUDY; DEMOGRAPHY; DRUG CONJUGATION; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPENIA; OSTEOPOROSIS; PATIENT SELECTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECORDING; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 0346365533     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(03)00158-1     Document Type: Article

References (50)

1. D'Angelo A., Sehlub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11.
2. Moustapha A., Robinson K. Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics. 54:1999;49-63.
3. Van Baal W.M., Smolders R.G.V., van der Mooren M.J., Teerlink T., Kenemans P. Hormone replacement therapy and plasma homocysteine levels. Obstet. Gynecol. 94:1999;485-491.
4. Mijatovic V., Kenemans P., Netelenbos C., Jacobs C., Popp-Snijders C., Peters-Muller E.R.et al. Postmenopausal oral 17β-estrdiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil. Steril. 69:1998;876-882.
5. Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 44:1998;1833-1843.
6. Ueland P.M., Refsum H., Stabler S.P., Malinow M.R., Andersson A., Allen R.H. Total homocysteine in plasma or serum: methods and clinical applications. Clin. Chem. 39:1993;1764-1779.
7. Hak A.E., Polderman K.H., Westendorp I.C., Jacobs C., Hofman A., Witteman J.C.et al. Increased plasma homocysteine after menopause. Atherosclerosis. 149:2000;163-168.
8. De Cree C., Malinow M.R., van Kranenburg G.P., Geurten P.G., Longford N.T., Keizer H.A. Influence of exercise and menstrual cycle phase on plasma homocysteine levels in young women - a prospective study. Scand. J. Med. Sci. Sports. 9:1999;272-278.
9. Tallova J., Tomandl J., Bicikova M., Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur. J. Clin. Invest. 29:1999;1041-1044.
10. Mijatovic V., Kenemans P., Jacobs C., van Baal W.M., Peters-Muller E.R., van der Mooren M.J. A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet. Gynecol. 91:1998;432-436.
11. Wouters M.G., Moorrees M.T., van der Mooren M.J., Blom H.J., Boers G.H., Schellekens L.A.et al. Plasma homocysteine and menopausal status. Eur. J. Clin. Invest. 25:1995;801-805.
12. Obwegeser R., Hohlagswandtner M., Sinzinger H. Homocysteine - a pathophysiological cornerstone in obstetrical and gynecological disorders. Hum. Reprod. Update. 5:1999;64-72.
13. Anderson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelt A., Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. Eur. J. Clin. Invest. 22:1992;79-87.
14. Christodoulakos G.E., Panoulis C.P.C., Rizos D.A., Moustakarias T., Phocas I., Creatsas G.C. Homocysteine and folate levels in postmenopausal women. Maturitas. 39:2001;161-167.
15. Morris M.S., Jacques P.F., Selhub J., Rosenberg I.U. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 152:2000;140-148.
16. Nazr A., Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol. Endocrinol. 12:1998;43-59.
17. Mijatovic V., van der Mooren M.J., Stehouwer C.D., Netelenbos J.C., Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol. Endocrinol. 13:1999;130-144.
18. Van der Mooren M.J., Mijatovic V., van Baal W.M., Stehouwer C.D.A. Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease. Maturitas. 30:1998;27-36.
19. Berger P.B., Herrmann R.R., Dumesic D.A. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin. Proc. 75:2000;18-23.
20. Evio S., Tiitinen A., Turpeinen U., Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil. Steril. 74:2000;1080-1083.
21. Nazr A., Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of the iceberg. Gynecol. Endocrinol. 12(1):1998;43-59.
22. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340:1999;1801-1811.
23. Godsland I.F. Effects of postmenopausal hormone replacement therapy on lipid, apolipoprotein and lipoprotein (α) concentrations: analysis of studies published from 1974-2000. Fertil. Steril. 75:2001;898-915.
24. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A.et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J. Clin. Endocrinol. Metab. 85:2000;214-218.
25. Barnabei V.M., Philips T.M., Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J. Womens Health Gend. Based Med. 8:1999;1167-1172.
26. Ventura P., Cagnacci A., Malmusi S., Panini R., Baldassari F., Arangino S.et al. Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause. 8:2001;252-258.
27. Kloosterboer H.J. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid. Biochem. Mol. Biol. 76:2001;231-238.
28. Stefanick M.L. Estrogen, progestogens and cardiovascular risk. J. Reprod. Med. 44:1999;221-226.
29. Wilcox J.G., Hatch I.E., Gentzschein E., Stanczyk F.Z., Lobo R.A. Endothelin levels decrease after oral and non-oral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil. Steril. 67:1997;273-277.
30. Christodoulakos G.E., Panoulis C.P.C., Kouskouni E., Chondros C., Dendrinos S.G., Creatsas G.C. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecol. Endocrinol. 16:2002;9-17.
31. Dimitrova K.R., DeGroot K., Kim Y.D. Estrogen and homocysteine. Cardiovasc. Res. 53:2002;577-588.
32. Mosharov E., Cranford M., Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 39:2000;13005-13011.
33. Mijatovic V., Netelenbos C., van der Mooren M.J., de Valk-de Roo G.W., Jacobs C., Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil. Steril. 70:1998;1085-1089.
34. De Leo V., la Marca A., Morgante G., Lanzetta D., Setacci C., Petraglia F. Randomized controlled study on the effects of raloxifene on serum lipids and homocysteine in older women. Am. J. Obstet. Gynecol. 184:2001;350-353.
35. Love R.R., Anker G., Yang Y., Refsum H., Ueland P.M., Lonning P.E.et al. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Lett. 18(145):1999;73-77.
36. Cattaneo M., Baglietto L., Zighetti M.L., Bettega D., Robertson C., Costa A.et al. Tamoxifen reduces plasma homocysteine levels in healthy women. Br. J. Cancer. 77:1998;2264-2266.
37. Park J.S., Jung H.H., Yang W.S., Kim S.B., Min W.K., Chi H.S. Effects of hormonal replacement therapy on lipid and haemostatic factors in post-menopausal ESRD patients. Nephrol. Dial Transplant. 15:2000;1835-1840.
38. Somekawa Y., Kobayashi K., Tomura S., Aso T., Hamaguchi H. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. Fertil. Steril. 77:2002;481-486.
39. Kim Y., Farhat M., Myers A.et al. 17-Beta estradiol regulation of myocardial glutathione and its role in protection against myocardial stunning in dogs. J. Cardiovasc. Pharmacol. 32:1998;457-465.
40. Dimitrova K.R., DeGroot K.W., Suyderhoud J.P.et al. 17-Beta estradiol preserves endothelial cell viability in an in vitro model of homocysteine-induced oxidative stress. J. Cardiovasc. Pharmacol. 39:2002;347-353.
41. Dimitrova K.R., DeGroot K.W., Pacquing A.M.et al. Estradiol prevents homocysteine-induced endothelial injury in male rats. Cardiovasc. Res. 53:2002;589-596.
42. Farish E., Barnes J.F., Fletcher C.D., Ekevall K., Calder A., Hart D.M. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause. 6:1999;98-104.
43. Bjarnason N.H., Bjarnason K., Haarbo J., Bennink H.J., Christiansen C. Tibolone: influence on markers of cardiovascular disease. J. Clin. Endocrinol. Metab. 82:1997;1752-1756.
44. Barnes J.F., Farish E., Rankin M., Hart D.M. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. Atherosclerosis. 160:2002;185-193.
45. von Eckardstein A., Schmiddem K., Hoevels A., Gulbahce E., Schuler-Luttmann S., Elbers J.et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 159(2):2001;433-439.
46. Morris E.P., Jamieson C.P., Robinson J., Obeid O.A., Powell-Tuck J., Rymer J.M. The effect of tibolone on plasma homocysteine levels in asymptomatic postmenopausal women. Fertil. Steril. 70:1998;S376.
47. Celic H., Ayar A., Tug N., Cikim G., Kilic N., Parmaksiz C. Effects of tibolone on plasma homocysteine levels in postmenopausal women. Fertil. Steril. 78:2002;347-350.
48. Castelo-Branco C., Vicente J., Figueras F.et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas. 34:2000;161-168.
49. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., Stehouwer C.D. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J. Clin. Endocrinol. Metab. 83:1998;550-553.
50. Madsen J.S., Kristensen S.R., Klitgaard N.A.et al. Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study. Am. J. Obstet. Gynecol. 187:2002;33-39.